CHEST is a premier journal published by Elsevier, focusing on the vital fields of cardiology, critical care, and pulmonary medicine. Established in 1970, this esteemed journal has continually provided authoritative research, reviews, and clinical studies, catering to a global audience of healthcare professionals, researchers, and students. With an impressive impact factor, CHEST ranks in the top quartile (Q1) across its core categories according to the latest Scopus metrics, securing its position as a leading resource within cardiology (Rank #16), pulmonary (Rank #9), and critical care (Rank #8). Published quarterly, it offers a wealth of knowledge essential for advancing understanding and improving patient outcomes in these critical areas of healthcare. Researchers and practitioners are encouraged to submit their work, contributing to the ongoing discourse that shapes innovative practices and policies in respiratory and cardiovascular health.

Chronic Respiratory Disease is a leading peer-reviewed journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by SAGE Publications Ltd since its inception in 2004, this open-access journal has been at the forefront of disseminating high-quality research aimed at addressing chronic respiratory conditions. With an impressive impact factor and classified as Q1 in the 2023 category of Pulmonary and Respiratory Medicine, it ranks an admirable #45 out of 155 in Scopus, placing it in the 71st percentile of its field. This journal features a diverse range of studies, reviews, and clinical insights that cater to researchers, healthcare professionals, and students alike, encouraging the exchange of innovative ideas and practices in respiratory disease management. Operating out of London, UK, Chronic Respiratory Disease exemplifies a commitment to openness, having transitioned to open access since 2017, thereby ensuring that pivotal research is readily accessible to a global audience engaged in the improvement of respiratory health.

BMC Pulmonary Medicine is a leading open access journal dedicated to the field of pulmonary and respiratory medicine, published by BMC since its inception in 2001. With an ISSN of 1471-2466, this journal plays a pivotal role in advancing knowledge and research dissemination in its field, maintaining a prominent position with a 2023 Scopus ranking of #65 out of 155 journals, placing it within the 58th percentile of the category. Based in the United Kingdom, it operates under a collaborative mission to provide unrestricted access to vital research, contributing to the global understanding of respiratory health issues. The journal is recognized for its commitment to high-quality, peer-reviewed research, as evidenced by its Q2 category designation in Pulmonary and Respiratory Medicine. BMC Pulmonary Medicine aims to foster innovation and scholarship among researchers, professionals, and students, making it an indispensable resource for anyone engaged in pulmonary research and practice. The journal, accessible to everyone, enables the dissemination of impactful research that can influence clinical practice and policy worldwide.

Minerva Respiratory Medicine is a prominent academic journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by EDIZIONI MINERVA MEDICA in Italy, this journal provides a vital platform for the dissemination of innovative research, clinical studies, and review articles that address the complexities of respiratory health. With an ISSN of 2784-8477 and an E-ISSN of 2724-6493, it serves as an open-access resource, allowing researchers, healthcare professionals, and students access to invaluable information without barriers. The journal is categorized in the fourth quartile of the 2023 rankings in the field of pulmonary and respiratory medicine, indicating its emerging role in the academic landscape. Despite its nascent status—converging from 2021 to 2024—Minerva Respiratory Medicine is committed to enhancing knowledge and practice in respiratory care, focusing on both innovative therapies and traditional approaches. With its aim to foster collaboration and communication among professionals in the field, this journal is an essential resource for those passionate about improving respiratory health outcomes.

Turkish Thoracic Journal, published by AVES, is a prominent open-access platform dedicated to advancing the field of pulmonary and respiratory medicine. Since its establishment, the journal has aimed to disseminate significant research findings, clinical studies, and reviews that contribute to an improved understanding of respiratory health challenges, with a particular focus on the Turkish context and regional issues. With an E-ISSN of 2149-2530 and transitioning to open access in 2022, the journal enhances visibility and accessibility, inviting a global audience of researchers, clinicians, and students to engage with the latest scientific work. The Turkish Thoracic Journal has been indexed in major databases, although it faced a coverage discontinuation in Scopus between 2016 and 2022. Currently positioned within the 23rd percentile among its peers in the field, it invites submissions that explore innovative approaches to thoracic health, enriching the discourse in a vital area of medicine.

The AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, published by the esteemed American Thoracic Society, is a premier platform dedicated to advancing knowledge in the fields of pulmonary and respiratory medicine, cell biology, and clinical biochemistry. With an impressive impact factor and recognition as a Q1 journal in multiple categories for 2023, it ranks among the top tier of scholarly publications, evidencing its influence and contribution to the scientific community. Since its inception in 1989, the journal has provided a critical forum for researchers and professionals to disseminate innovative findings and pivotal reviews, driving forward the frontiers of respiratory biology. While the journal currently operates under traditional access mechanisms, it seeks to bridge gaps in research by presenting high-quality articles that address vital health challenges. As a key resource for both established researchers and emerging scholars in molecular biology and respiratory science, this journal plays a pivotal role in shaping the future of respiratory health advancements.

Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

Welcome to the Journal of Thoracic Disease, a premier scholarly journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by AME PUBLISHING COMPANY in Hong Kong, this journal has established itself as a critical platform for the dissemination of innovative research and clinical advancements since its inception in 2009. With an impressive Q2 ranking in the Scopus category of Pulmonary and Respiratory Medicine, it is recognized for its contribution to the academic community, featuring a broad range of original research, reviews, and case studies that address contemporary challenges in thoracic disease management. The journal is committed to Open Access principles, ensuring that high-quality research is readily available to a global audience, further enhancing its impact factor and reach. Researchers, healthcare professionals, and students alike will find invaluable insights within its pages, making Journal of Thoracic Disease an essential resource for those invested in the respiratory health domain.

Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.